IRONWOOD PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense, Tax Benefit
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Share-based Payment Arrangement, Expense, Tax Benefit of -$846.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2026-06-30 was -$846.00K.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2026-03-31 was $1.55M, a 54.91% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2025-12-31 was -$46.00K, a 100.73% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2025-09-30 was -$344.00K.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for fiscal 2025 was $2.52M, a 26.22% decline from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for fiscal 2024 was $3.41M, a 15.18% increase from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for fiscal 2023 was $2.96M, a 80.29% increase from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for fiscal 2022 was $1.64M.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 3 month | Share-based Payment Arrangement, Expense, Tax Benefit 3 month as first filed | Share-based Payment Arrangement, Expense, Tax Benefit 6 month | Share-based Payment Arrangement, Expense, Tax Benefit 6 month as first filed | Share-based Payment Arrangement, Expense, Tax Benefit 9 month | Share-based Payment Arrangement, Expense, Tax Benefit 9 month as first filed | Share-based Payment Arrangement, Expense, Tax Benefit 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$846.00K 10-Q · filed 2026-08-06 | $705.00K 10-Q · filed 2026-08-06 | $659.00K derived: sum of 3 quarters · filed 2026-08-06 | $315.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $1.55M 10-Q · filed 2026-05-07 | $1.50M derived: sum of 2 quarters · filed 2026-05-07 | $1.16M derived: sum of 3 quarters · filed 2026-05-07 | $629.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$390.00K derived: sum of 2 quarters · filed 2026-02-26 | -$922.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.52M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$344.00K 10-Q · filed 2025-11-10 | -$876.00K derived: sum of 2 quarters · filed 2026-08-06 | $2.56M 10-Q · filed 2025-11-10 | $8.83M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$532.00K 10-Q · filed 2026-08-06 | $2.91M 10-Q · filed 2026-08-06 | $9.18M derived: sum of 3 quarters · filed 2026-08-06 | $8.34M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $3.44M 10-Q · filed 2026-05-07 | $9.71M derived: sum of 2 quarters · filed 2026-05-07 | $8.87M derived: sum of 3 quarters · filed 2026-05-07 | $8.22M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $6.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.43M derived: sum of 2 quarters · filed 2026-02-26 | $4.78M derived: sum of 3 quarters · filed 2026-02-26 | $3.41M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$840.00K 10-Q · filed 2025-11-10 | $840.00K 10-Q · filed 2024-11-07 | -$1.49M derived: sum of 2 quarters · filed 2025-11-10 | -$2.85M 10-Q · filed 2025-11-10 | $2.85M 10-Q · filed 2024-11-07 | -$1.96M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$648.00K 10-Q · filed 2025-08-11 | $648.00K 10-Q · filed 2024-08-08 | -$2.01M 10-Q · filed 2025-08-11 | $2.01M 10-Q · filed 2024-08-08 | -$1.12M derived: sum of 3 quarters · filed 2025-08-11 | -$268.00K derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$1.36M 10-Q · filed 2025-05-12 | $1.36M 10-Q · filed 2024-05-09 | -$470.00K derived: sum of 2 quarters · filed 2025-05-12 | $380.00K derived: sum of 3 quarters · filed 2025-05-12 | $1.30M derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $895.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.75M derived: sum of 2 quarters · filed 2025-03-31 | $2.67M derived: sum of 3 quarters · filed 2025-03-31 | $2.96M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $850.00K 10-Q · filed 2024-11-07 | -$850.00K 10-Q · filed 2023-11-09 | $1.77M derived: sum of 2 quarters · filed 2024-11-07 | $2.07M 10-Q · filed 2024-11-07 | -$2.07M 10-Q · filed 2023-11-09 | $2.99M derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-06-30 | $923.00K 10-Q · filed 2024-08-08 | $1.22M 10-Q · filed 2024-08-08 | $2.14M derived: sum of 3 quarters · filed 2025-03-31 | $3.31M derived: sum of 4 quarters · filed 2025-03-31 | |||
| 2023-03-31 | $297.00K 10-Q · filed 2024-05-09 | $1.22M derived: sum of 2 quarters · filed 2025-03-31 | $2.38M derived: sum of 3 quarters · filed 2025-03-31 | $2.66M derived: sum of 4 quarters · filed 2025-03-31 | |||
| 2022-12-31 | $920.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.08M derived: sum of 2 quarters · filed 2025-03-31 | $2.36M derived: sum of 3 quarters · filed 2025-03-31 | $1.64M 10-K · filed 2025-03-31 | |||
| 2022-09-30 | $1.17M 10-Q · filed 2023-11-09 | $1.44M derived: sum of 2 quarters · filed 2023-11-09 | $724.00K 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | $278.00K 10-Q · filed 2023-08-09 | -$442.00K 10-Q · filed 2023-08-09 | |||||
| 2022-03-31 | -$720.00K 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |